Sera Prognostics, Inc. (SERA) Research

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

Market snapshot

Symbol
SERA
Price
$1.75
Day change
-7.41%
Market cap
$66.8M
P/E ratio
-2.74x
52-week range
1.56-4.09
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months
Analyst price target
$6.00

Peer companies

  • Apyx Medical Corporation (APYX)
  • Atossa Therapeutics, Inc. (ATOS)
  • Cognition Therapeutics, Inc. (CGTX)
  • TuHURA Biosciences, Inc. (HURA)
  • Lucid Diagnostics Inc. (LUCD)
  • Oncolytics Biotech Inc. (ONCY)
  • Rapid Micro Biosystems, Inc. (RPID)
  • Surrozen, Inc. (SRZN)

Recent insider activity

  • Anderson Dyaarl Lee Jr. — S-Sale (4739 shares) on 2026-06-11
  • Aerts Austin — S-Sale (2037 shares) on 2026-06-11
  • Lindgardt Zhenya — S-Sale (6990 shares) on 2026-06-11
  • Inglis Tiffany Eul Davis — S-Sale (362 shares) on 2026-06-11
  • Jackson Benjamin — S-Sale (2179 shares) on 2026-06-11

Open Sera Prognostics, Inc. (SERA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.